Project Grant R01AI189313
Award Date
6/17/25
Completion Date
5/31/30
Dollars Obligated
$906K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78227, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute to study mechanisms for controlling Mycobacterium tuberculosis (MTB) infection in the lungs. The project aims to understand the immune responses generated by an attenuated, live-replicating MTB strain that has demonstrated protective efficacy in non-human primate models....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $711,993 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Boston Medical Center Corporation (BMC) to study the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The project aims to investigate how MTB disease impacts the development of broadly potent HIV-1 neutralizing antibodies, the emergence of antibody-resistant HIV-1 strains, and the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,200 to study the mechanisms of interferon-gamma (IFN-γ)-independent T cell and B cell-mediated protection against tuberculosis (TB) in humans. The research aims to elucidate the IFN-γ-independent T cell response and characterize the B cell, antibody, and T follicular helper (Tfh) cell responses in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on understanding the molecular basis for differences in vaccine efficacy between various sub-strains of the Bacillus Calmette-Guérin (BCG) tuberculosis vaccine. The total funding amount is $749,192, awarded on November 22, 2024, with a completion date of October 31, 2029. The key objectives of this research project...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the sirtuin-dependent regulation of tuberculosis (TB) and HIV interactions in macrophages. The total award amount is $1,297,775.00 over a 5-year period from August 1, 2024 to July 31, 2029. The primary objectives are to: 1) analyze the impact of early TB and HIV infection on sirtuin gene and protein...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $820,246 to the Albert Einstein College of Medicine to identify and characterize the specific proteins secreted by the ESX5 transport system of the tuberculosis (TB) bacterium. The research aims to determine the role of these secreted proteins in causing TB disease and the immunological basis for why an ESX5 mutant...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $447,009 to the University of Massachusetts to conduct research on the early immune response to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) Categorize alveolar macrophage sensing abilities and defects in responding to MTB pathogen-associated molecular patterns, and screen for novel...
This Project Grant award of $209,750 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to leverage antibody-based "omics" approaches to prevent and detect tuberculosis (TB) in children affected by HIV. The key objectives are to: Define antibody Fc (fragment crystallizable) features associated with protection from Mycobacterium tuberculosis (MTB) infection in infants with and without...
This $1,011,348 five-year Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the impact of HIV infection on the alveolar environment and how this affects early interactions between Mycobacterium tuberculosis (M.TB) and alveolar cells. The research aims to: 1) determine how M.TB exposure to alveolar lining fluid (ALF) from people living with HIV...